NASDAQ:ATNX - Athenex Stock Price, Price Target & More

$16.06 -0.10 (-0.62 %)
(As of 04/25/2018 02:37 AM ET)
Previous Close$16.06
Today's Range$15.94 - $16.38
52-Week Range$11.21 - $20.79
Volume137,344 shs
Average Volume340,461 shs
Market Capitalization$1.03 billion
P/E Ratio-6.92
Dividend YieldN/A
BetaN/A

About Athenex (NASDAQ:ATNX)

Athenex logoAthenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Its Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. The company also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is based in Buffalo, New York.

Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATNX
CUSIPN/A
Phone716-427-2950

Debt

Debt-to-Equity Ratio0.01%
Current Ratio1.86%
Quick Ratio1.49%

Price-To-Earnings

Trailing P/E Ratio-6.92
Forward P/E Ratio-11.47
P/E GrowthN/A

Sales & Book Value

Annual Sales$38.04 million
Price / Sales26.80
Cash FlowN/A
Price / CashN/A
Book Value$1.45 per share
Price / Book11.08

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees477
Outstanding Shares63,490,000

How to Become a New Pot Stock Millionaire

Athenex (NASDAQ:ATNX) Frequently Asked Questions

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

How were Athenex's earnings last quarter?

Athenex (NASDAQ:ATNX) posted its quarterly earnings data on Monday, March, 26th. The company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.33. The company earned $14.87 million during the quarter. View Athenex's Earnings History.

What price target have analysts set for ATNX?

6 brokerages have issued twelve-month price objectives for Athenex's shares. Their forecasts range from $20.00 to $36.00. On average, they anticipate Athenex's share price to reach $28.1667 in the next twelve months. View Analyst Ratings for Athenex.

Who are some of Athenex's key competitors?

Who are Athenex's key executives?

Athenex's management team includes the folowing people:
  • Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 58)
  • Mr. Jeffrey M. Yordon, COO & Pres of Pharmaceutical Division (Age 69)
  • Dr. Rudolf Kwan, Exec. VP & Chief Medical Officer (Age 65)
  • Mr. Kam Chung Leung GBS, LLD, OBE, JP, Strategic & Bus. Advisor (Age 66)
  • Dr. Allen Barnett Ph.D., Co-Founder and Pres Emeritus

When did Athenex IPO?

(ATNX) raised $72 million in an IPO on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

Has Athenex been receiving favorable news coverage?

News headlines about ATNX stock have been trending somewhat positive recently, according to Accern Sentiment. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Athenex earned a news sentiment score of 0.20 on Accern's scale. They also assigned news articles about the company an impact score of 44.92 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $16.06.

How big of a company is Athenex?

Athenex has a market capitalization of $1.03 billion and generates $38.04 million in revenue each year. The company earns $-131,170,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Athenex employs 477 workers across the globe.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950.


MarketBeat Community Rating for Athenex (ATNX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  186
MarketBeat's community ratings are surveys of what our community members think about Athenex and other stocks. Vote "Outperform" if you believe ATNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Athenex (NASDAQ:ATNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Athenex in the last 12 months. Their average twelve-month price target is $28.1667, suggesting that the stock has a possible upside of 75.38%. The high price target for ATNX is $36.00 and the low price target for ATNX is $20.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.802.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.1667$28.1667$27.80$27.64
Price Target Upside: 75.38% upside76.26% upside91.99% upside62.21% upside

Athenex (NASDAQ:ATNX) Consensus Price Target History

Price Target History for Athenex (NASDAQ:ATNX)

Athenex (NASDAQ:ATNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/6/2018Needham & Company LLCInitiated CoverageBuy -> Buy$30.00HighView Rating Details
1/24/2018JPMorgan ChaseBoost Price TargetNeutral -> Neutral$22.20 -> $23.00LowView Rating Details
1/17/2018Deutsche BankSet Price TargetBuy$20.00HighView Rating Details
9/19/2017LaidlawInitiated CoverageBuy$36.00MediumView Rating Details
9/18/2017Credit Suisse GroupInitiated CoverageOutperform -> Outperform$25.00LowView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$35.00HighView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Athenex (NASDAQ:ATNX) Earnings History and Estimates Chart

Earnings by Quarter for Athenex (NASDAQ:ATNX)

Athenex (NASDAQ:ATNX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.4 EPS
Next Year EPS Consensus Estimate: $-1.02 EPS

Athenex (NASDAQ ATNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018Q4 2017($0.16)($0.4940)$14.87 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.30)$13.99 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.88)$4.60 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Athenex (NASDAQ:ATNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Athenex (NASDAQ ATNX) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 5.83%
Insider Trading History for Athenex (NASDAQ:ATNX)
Institutional Ownership by Quarter for Athenex (NASDAQ:ATNX)

Athenex (NASDAQ ATNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2018Jeffrey YordonInsiderBuy5,000$14.69$73,450.00188,709View SEC Filing  
3/26/2018Jinn WuDirectorBuy10,000$14.66$146,600.00259,208View SEC Filing  
3/26/2018Johnson Yiu Nam LauCEOBuy12,500$14.76$184,500.002,780,422View SEC Filing  
3/26/2018Rudolf KwanEVPBuy2,000$14.65$29,300.0082,224View SEC Filing  
2/9/2018Jinn WuDirectorBuy10,000$13.64$136,400.00249,208View SEC Filing  
2/8/2018Johnson Yiu Nam LauCEOBuy20,000$14.40$288,000.002,767,922View SEC Filing  
2/7/2018Manson FokDirectorBuy30,000$14.31$429,300.001,799,609View SEC Filing  
6/19/2017Johnson Yiu Nam LauCEOBuy25,200$11.00$277,200.002,722,722View SEC Filing  
6/19/2017Song-Yi ZhangDirectorBuy328,637$11.00$3,615,007.004,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Athenex (NASDAQ ATNX) News Headlines

Source:
DateHeadline
Athenex (ATNX) Announces U.S. FDA Orphan Drug Designation for Oraxol for Treatment of AngiosarcomaAthenex (ATNX) Announces U.S. FDA Orphan Drug Designation for Oraxol for Treatment of Angiosarcoma
www.streetinsider.com - April 20 at 9:45 AM
Athenex (ATNX) Stock Rating Lowered by BidaskClubAthenex (ATNX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 19 at 11:10 AM
Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of AngiosarcomaAthenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma
finance.yahoo.com - April 19 at 9:33 AM
Report: Exploring Fundamental Drivers Behind Exponent, Monotype Imaging, Athenex, State Street, Heartland Financial, and IRSA Inversiones Y Representaciones S.A — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Exponent, Monotype Imaging, Athenex, State Street, Heartland Financial, and IRSA Inversiones Y Representaciones S.A — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - April 18 at 9:34 AM
Athenex (ATNX) Given Average Recommendation of "Buy" by AnalystsAthenex (ATNX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 14 at 3:30 AM
Athenex (ATNX) Stock Rating Upgraded by BidaskClubAthenex (ATNX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 11 at 11:30 AM
Athenex (ATNX) Upgraded to "Buy" at Zacks Investment ResearchAthenex (ATNX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 10 at 8:28 AM
Athenex production leaders lean on experience from Fresenius-Kabi, Thermo-FisherAthenex production leaders lean on experience from Fresenius-Kabi, Thermo-Fisher
finance.yahoo.com - April 6 at 4:36 PM
Athenex (ATNX) Rating Lowered to Hold at Zacks Investment ResearchAthenex (ATNX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 30 at 5:40 PM
Athenex (ATNX) Rating Increased to Buy at Zacks Investment ResearchAthenex (ATNX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:48 PM
Athenex (ATNX) Given a $20.00 Price Target by Deutsche Bank AnalystsAthenex (ATNX) Given a $20.00 Price Target by Deutsche Bank Analysts
www.americanbankingnews.com - March 27 at 8:34 PM
Athenex (ATNX) Rating Increased to Hold at BidaskClubAthenex (ATNX) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 27 at 4:00 PM
Athenex to Present at the 17th Annual Needham Healthcare ConferenceAthenex to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 27 at 10:03 AM
Athenex (ATNX) Announces Quarterly  Earnings Results, Misses Estimates By $0.33 EPSAthenex (ATNX) Announces Quarterly Earnings Results, Misses Estimates By $0.33 EPS
www.americanbankingnews.com - March 27 at 9:38 AM
Insider Buying: Athenex Inc (ATNX) EVP Purchases 2,000 Shares of StockInsider Buying: Athenex Inc (ATNX) EVP Purchases 2,000 Shares of Stock
www.americanbankingnews.com - March 26 at 10:45 PM
Insider Buying: Athenex Inc (ATNX) Insider Purchases 5,000 Shares of StockInsider Buying: Athenex Inc (ATNX) Insider Purchases 5,000 Shares of Stock
www.americanbankingnews.com - March 26 at 10:44 PM
Athenex Inc (ATNX) Director Jinn Wu Buys 10,000 SharesAthenex Inc (ATNX) Director Jinn Wu Buys 10,000 Shares
www.americanbankingnews.com - March 26 at 10:26 PM
Insider Buying: Athenex Inc (ATNX) CEO Buys 12,500 Shares of StockInsider Buying: Athenex Inc (ATNX) CEO Buys 12,500 Shares of Stock
www.americanbankingnews.com - March 26 at 10:26 PM
Athenex Loses on Full-Year NumbersAthenex Loses on Full-Year Numbers
www.baystreet.ca - March 26 at 4:16 PM
Athenex, Inc. Announces Fourth Quarter and Full-Year 2017 ResultsAthenex, Inc. Announces Fourth Quarter and Full-Year 2017 Results
finance.yahoo.com - March 26 at 9:59 AM
Athenex reports 4Q lossAthenex reports 4Q loss
finance.yahoo.com - March 26 at 9:59 AM
Athenex (ATNX) Downgraded to "Hold" at Zacks Investment ResearchAthenex (ATNX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 22 at 5:49 PM
Athenex Inc (ATNX) Given Consensus Recommendation of "Buy" by BrokeragesAthenex Inc (ATNX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 20 at 3:34 AM
Athenex (ATNX) Upgraded by BidaskClub to BuyAthenex (ATNX) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 14 at 8:31 PM
Athenex (ATNX) Now Covered by Analysts at Needham & Company LLCAthenex (ATNX) Now Covered by Analysts at Needham & Company LLC
www.americanbankingnews.com - March 6 at 10:20 PM
Athenex Inc’s (NASDAQ:ATNX) Shift From Loss To ProfitAthenex Inc’s (NASDAQ:ATNX) Shift From Loss To Profit
finance.yahoo.com - March 2 at 9:25 AM
Athenex, Inc. to Report Fourth Quarter and Full Year 2017 Earnings Results on March 26, 2018Athenex, Inc. to Report Fourth Quarter and Full Year 2017 Earnings Results on March 26, 2018
finance.yahoo.com - February 26 at 9:27 AM
Tax breaks approved for Athenex and TomricTax breaks approved for Athenex and Tomric
finance.yahoo.com - February 23 at 4:51 PM
Athenex Inc (ATNX) Receives Consensus Recommendation of "Buy" from AnalystsAthenex Inc (ATNX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 23 at 3:30 AM
Athenex to Present at 2018 RBC Capital Markets Healthcare ConferenceAthenex to Present at 2018 RBC Capital Markets Healthcare Conference
finance.yahoo.com - February 16 at 9:11 AM
Athenex (ATNX) Reports Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic KeratosisAthenex (ATNX) Reports Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
www.streetinsider.com - February 15 at 4:31 PM
Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast CancerAthenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer
finance.yahoo.com - February 15 at 8:49 AM
Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic KeratosisAthenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
finance.yahoo.com - February 14 at 9:06 AM
Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business UnitsAthenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units
finance.yahoo.com - February 13 at 9:05 AM
Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $288,000 of SharesAthenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $288,000 of Shares
finance.yahoo.com - February 10 at 9:00 AM
Insider Buying: Athenex Inc (ATNX) Director Buys 10,000 Shares of StockInsider Buying: Athenex Inc (ATNX) Director Buys 10,000 Shares of Stock
www.americanbankingnews.com - February 9 at 6:32 PM
Johnson Yiu Nam Lau Purchases 20,000 Shares of Athenex Inc (ATNX) StockJohnson Yiu Nam Lau Purchases 20,000 Shares of Athenex Inc (ATNX) Stock
www.americanbankingnews.com - February 9 at 6:20 PM
Insider Buying: Athenex Inc (ATNX) Director Acquires 30,000 Shares of StockInsider Buying: Athenex Inc (ATNX) Director Acquires 30,000 Shares of Stock
www.americanbankingnews.com - February 9 at 6:20 PM
Athenex Inc (ATNX) Receives Consensus Rating of "Buy" from BrokeragesAthenex Inc (ATNX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 29 at 3:32 AM
Athenex (ATNX) Given New $23.00 Price Target at JPMorgan Chase & Co.Athenex (ATNX) Given New $23.00 Price Target at JPMorgan Chase & Co.
www.americanbankingnews.com - January 28 at 2:22 PM
Athenex, Inc. Announces Pricing of Offering of Common StockAthenex, Inc. Announces Pricing of Offering of Common Stock
finance.yahoo.com - January 25 at 9:05 AM
Wired News – Athenex Announced Positive Results of Phase-I Clinical Trial of Oraxol and CYRAMZA(R) Combination Treatment in Gastric CancerWired News – Athenex Announced Positive Results of Phase-I Clinical Trial of Oraxol and CYRAMZA(R) Combination Treatment in Gastric Cancer
finance.yahoo.com - January 24 at 9:31 AM
Athenex (ATNX) Announces Proposed 4.3M Common Share OfferingAthenex (ATNX) Announces Proposed 4.3M Common Share Offering
www.streetinsider.com - January 22 at 5:47 PM
Athenex (ATNX) & Its Peers Head to Head SurveyAthenex (ATNX) & Its Peers Head to Head Survey
www.americanbankingnews.com - January 17 at 3:12 AM
Athenex (ATNX) Reports Positive Feedback from FDA on Design of Phase III Clinical Trial for OraxolAthenex (ATNX) Reports Positive Feedback from FDA on Design of Phase III Clinical Trial for Oraxol
www.streetinsider.com - January 16 at 9:05 AM
Athenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for OraxolAthenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for Oraxol
finance.yahoo.com - January 16 at 9:05 AM
Athenex signs general contractor for 320,000-square-foot factory in DunkirkAthenex signs general contractor for 320,000-square-foot factory in Dunkirk
finance.yahoo.com - January 9 at 5:59 PM
Investors Are Undervaluing Athenex Inc (NASDAQ:ATNX) By 35.71%, Here Is My Intrinsic Value CalculationInvestors Are Undervaluing Athenex Inc (NASDAQ:ATNX) By 35.71%, Here Is My Intrinsic Value Calculation
finance.yahoo.com - January 9 at 9:04 AM
Athenex (ATNX) Granted Allowance from Chinese FDA of Investigational New Drug Application of Oraxol to Begin Clinical TrialsAthenex (ATNX) Granted Allowance from Chinese FDA of Investigational New Drug Application of Oraxol to Begin Clinical Trials
www.streetinsider.com - January 8 at 5:57 PM
Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical TrialsAthenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials
finance.yahoo.com - January 8 at 12:05 PM

SEC Filings

Athenex (NASDAQ:ATNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Athenex (NASDAQ:ATNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Athenex (NASDAQ ATNX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.